Related Experiment Video
Updated: Jun 12, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Macrocyclic histone deacetylase inhibitors
Sandra C Mwakwari1, Vishal Patil, William Guerrant
1Parker H. Petit Institute of Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, 30332-0400, USA.
Abstract:
Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells. In addition, they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatologic and immunosuppressant agents. To date, several structurally distinct small molecule HDACi have been reported including aryl hydroxamates, benzamides, short-chain fatty acids, electrophilic ketones, and macrocyclic peptides. Macrocyclic HDACi possess the most complex cap-groups which interact with HDAC enzyme's outer rim and have demonstrated excellent HDAC inhibition potency and isoform selectivity. This review focuses on the recent progress and current state of macrocyclic HDACi.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Inhibitors of Viral Protein Synthesis
Heterochromatin
Constitutive heterochromatin: It is a highly compact region of chromatin that is mostly concentrated in the centromere and telomere. Unlike euchromatin, the amino acid at 9th...
Anaphase Promoting Complex

